CA2116753C - Anticorps monoclonaux reconnaissant le recepteur du facteur de croissance epidermique (egf), celluces et methodes de production et compositions contenant ces anticorps - Google Patents

Anticorps monoclonaux reconnaissant le recepteur du facteur de croissance epidermique (egf), celluces et methodes de production et compositions contenant ces anticorps Download PDF

Info

Publication number: CA2116753C
Authority: CA; Canada
Prior art keywords: monoclonal antibody; egf; cells; receptor; producing
Prior art date: 1993-03-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA 2116753

Other languages

English (en)

Other versions

CA2116753A1 (fr

Inventor

Alicia F. Ordonez

Cristina M. Mateo De Acosta Del Rio

Amparo E. M. Abraham

Pedro P. M. Perez

Blanca R. T. Bravo

Rolando P. Rodriguez

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Centro de Immunologia Molecular

Original Assignee

Centro de Immunologia Molecular

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-03-01

Filing date

1994-03-01

Publication date

2001-09-04

1994-03-01 Application filed by Centro de Immunologia Molecular filed Critical Centro de Immunologia Molecular

1994-09-02 Publication of CA2116753A1 publication Critical patent/CA2116753A1/fr

2001-09-04 Application granted granted Critical

2001-09-04 Publication of CA2116753C publication Critical patent/CA2116753C/fr

2014-03-01 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

102000001301 EGF receptor Human genes 0.000 title claims abstract description 62
108060006698 EGF receptor Proteins 0.000 title claims abstract description 56
238000000034 method Methods 0.000 title claims description 39
239000000203 mixture Substances 0.000 title claims description 11
230000002401 inhibitory effect Effects 0.000 claims abstract description 41
230000035755 proliferation Effects 0.000 claims abstract description 32
102000005962 receptors Human genes 0.000 claims abstract description 32
108020003175 receptors Proteins 0.000 claims abstract description 32
230000002195 synergetic effect Effects 0.000 claims abstract description 32
230000000295 complement effect Effects 0.000 claims abstract description 28
230000001404 mediated effect Effects 0.000 claims abstract description 23
230000001472 cytotoxic effect Effects 0.000 claims abstract description 20
150000002270 gangliosides Chemical class 0.000 claims abstract description 19
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims abstract description 18
230000012010 growth Effects 0.000 claims abstract description 17
230000001173 tumoral effect Effects 0.000 claims abstract description 3
102000009024 Epidermal Growth Factor Human genes 0.000 claims abstract 13
210000004027 cell Anatomy 0.000 claims description 112
101800003838 Epidermal growth factor Proteins 0.000 claims description 58
229940116977 epidermal growth factor Drugs 0.000 claims description 58
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 55
210000004408 hybridoma Anatomy 0.000 claims description 51
206010028980 Neoplasm Diseases 0.000 claims description 31
210000004881 tumor cell Anatomy 0.000 claims description 25
230000000694 effects Effects 0.000 claims description 23
230000001225 therapeutic effect Effects 0.000 claims description 17
201000011510 cancer Diseases 0.000 claims description 13
208000020816 lung neoplasm Diseases 0.000 claims description 13
238000012360 testing method Methods 0.000 claims description 13
206010035226 Plasma cell myeloma Diseases 0.000 claims description 12
239000001963 growth medium Substances 0.000 claims description 12
201000000050 myeloid neoplasm Diseases 0.000 claims description 12
230000000890 antigenic effect Effects 0.000 claims description 10
230000001419 dependent effect Effects 0.000 claims description 10
239000002609 medium Substances 0.000 claims description 10
GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 claims description 10
201000010099 disease Diseases 0.000 claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
239000012634 fragment Substances 0.000 claims description 8
230000003053 immunization Effects 0.000 claims description 8
241001465754 Metazoa Species 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
230000001855 preneoplastic effect Effects 0.000 claims description 7
101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 claims description 6
108060003951 Immunoglobulin Proteins 0.000 claims description 5
-1 N-acetyl GM3 ganglioside Chemical class 0.000 claims description 5
125000003047 N-acetyl group Chemical group 0.000 claims description 5
210000000628 antibody-producing cell Anatomy 0.000 claims description 5
230000003013 cytotoxicity Effects 0.000 claims description 5
231100000135 cytotoxicity Toxicity 0.000 claims description 5
102000018358 immunoglobulin Human genes 0.000 claims description 5
230000003169 placental effect Effects 0.000 claims description 5
101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 claims description 4
229940116978 human epidermal growth factor Drugs 0.000 claims description 4
238000002649 immunization Methods 0.000 claims description 4
238000000338 in vitro Methods 0.000 claims description 4
238000011321 prophylaxis Methods 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
208000037841 lung tumor Diseases 0.000 claims 2
241000283984 Rodentia Species 0.000 claims 1
210000001124 body fluid Anatomy 0.000 claims 1
239000010839 body fluid Substances 0.000 claims 1
238000001727 in vivo Methods 0.000 claims 1
238000000926 separation method Methods 0.000 claims 1
210000002826 placenta Anatomy 0.000 abstract description 16
102400001368 Epidermal growth factor Human genes 0.000 description 47
230000005764 inhibitory process Effects 0.000 description 24
230000001413 cellular effect Effects 0.000 description 20
239000006228 supernatant Substances 0.000 description 19
238000010187 selection method Methods 0.000 description 16
238000006243 chemical reaction Methods 0.000 description 14
210000001519 tissue Anatomy 0.000 description 14
238000011282 treatment Methods 0.000 description 14
235000018102 proteins Nutrition 0.000 description 13
102000004169 proteins and genes Human genes 0.000 description 13
108090000623 proteins and genes Proteins 0.000 description 13
239000000427 antigen Substances 0.000 description 11
108091007433 antigens Proteins 0.000 description 11
102000036639 antigens Human genes 0.000 description 11
238000002360 preparation method Methods 0.000 description 11
230000004614 tumor growth Effects 0.000 description 11
206010058467 Lung neoplasm malignant Diseases 0.000 description 10
239000012636 effector Substances 0.000 description 10
201000005202 lung cancer Diseases 0.000 description 10
239000000725 suspension Substances 0.000 description 10
206010006187 Breast cancer Diseases 0.000 description 9
230000004927 fusion Effects 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
230000004663 cell proliferation Effects 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
210000004989 spleen cell Anatomy 0.000 description 7
208000026310 Breast neoplasm Diseases 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 6
229940079593 drug Drugs 0.000 description 6
239000003814 drug Substances 0.000 description 6
239000003937 drug carrier Substances 0.000 description 6
241000699670 Mus sp. Species 0.000 description 5
229910002092 carbon dioxide Inorganic materials 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
239000003102 growth factor Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
238000000691 measurement method Methods 0.000 description 5
230000009257 reactivity Effects 0.000 description 5
238000011160 research Methods 0.000 description 5
210000000952 spleen Anatomy 0.000 description 5
208000010507 Adenocarcinoma of Lung Diseases 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
102000009465 Growth Factor Receptors Human genes 0.000 description 4
108010009202 Growth Factor Receptors Proteins 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
230000000996 additive effect Effects 0.000 description 4
210000000481 breast Anatomy 0.000 description 4
230000010261 cell growth Effects 0.000 description 4
201000007455 central nervous system cancer Diseases 0.000 description 4
208000025997 central nervous system neoplasm Diseases 0.000 description 4
238000012512 characterization method Methods 0.000 description 4
231100000433 cytotoxic Toxicity 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
239000012528 membrane Substances 0.000 description 4
230000003228 microsomal effect Effects 0.000 description 4
239000003053 toxin Substances 0.000 description 4
231100000765 toxin Toxicity 0.000 description 4
108700012359 toxins Proteins 0.000 description 4
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
241001529936 Murinae Species 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
244000309466 calf Species 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000012875 competitive assay Methods 0.000 description 3
230000001461 cytolytic effect Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
229940061607 dibasic sodium phosphate Drugs 0.000 description 3
235000013681 dietary sucrose Nutrition 0.000 description 3
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
239000000284 extract Substances 0.000 description 3
230000009036 growth inhibition Effects 0.000 description 3
210000003128 head Anatomy 0.000 description 3
229940072221 immunoglobulins Drugs 0.000 description 3
238000011534 incubation Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
239000011630 iodine Substances 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
229960002160 maltose Drugs 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
229940045641 monobasic sodium phosphate Drugs 0.000 description 3
229910000403 monosodium phosphate Inorganic materials 0.000 description 3
235000019799 monosodium phosphate Nutrition 0.000 description 3
210000003739 neck Anatomy 0.000 description 3
210000001672 ovary Anatomy 0.000 description 3
210000002741 palatine tonsil Anatomy 0.000 description 3
210000000496 pancreas Anatomy 0.000 description 3
210000003024 peritoneal macrophage Anatomy 0.000 description 3
229940085675 polyethylene glycol 800 Drugs 0.000 description 3
238000003752 polymerase chain reaction Methods 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
229940068968 polysorbate 80 Drugs 0.000 description 3
230000002265 prevention Effects 0.000 description 3
210000002307 prostate Anatomy 0.000 description 3
239000002356 single layer Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
239000000243 solution Substances 0.000 description 3
229960004793 sucrose Drugs 0.000 description 3
210000001550 testis Anatomy 0.000 description 3
210000001685 thyroid gland Anatomy 0.000 description 3
229940074410 trehalose Drugs 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
206010003445 Ascites Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
208000032612 Glial tumor Diseases 0.000 description 2
206010018338 Glioma Diseases 0.000 description 2
206010062767 Hypophysitis Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
210000004100 adrenal gland Anatomy 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
229960003896 aminopterin Drugs 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
230000003305 autocrine Effects 0.000 description 2
230000035578 autophosphorylation Effects 0.000 description 2
238000011888 autopsy Methods 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
201000008274 breast adenocarcinoma Diseases 0.000 description 2
239000000872 buffer Substances 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
230000005889 cellular cytotoxicity Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
230000004807 localization Effects 0.000 description 2
201000005249 lung adenocarcinoma Diseases 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 2
102000006240 membrane receptors Human genes 0.000 description 2
108020004084 membrane receptors Proteins 0.000 description 2
210000005087 mononuclear cell Anatomy 0.000 description 2
239000013642 negative control Substances 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
208000029974 neurofibrosarcoma Diseases 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000012071 phase Substances 0.000 description 2
210000005152 placental membrane Anatomy 0.000 description 2
239000004800 polyvinyl chloride Substances 0.000 description 2
229920000915 polyvinyl chloride Polymers 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000000700 radioactive tracer Substances 0.000 description 2
239000000523 sample Substances 0.000 description 2
238000012216 screening Methods 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
238000010361 transduction Methods 0.000 description 2
230000026683 transduction Effects 0.000 description 2
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
239000012224 working solution Substances 0.000 description 2
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
229960005508 8-azaguanine Drugs 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
241000521299 Deinocerites cancer Species 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
206010053717 Fibrous histiocytoma Diseases 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
206010025538 Malignant ascites Diseases 0.000 description 1
206010064912 Malignant transformation Diseases 0.000 description 1
101710169972 Menin Proteins 0.000 description 1
102100030550 Menin Human genes 0.000 description 1
208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
OAICVXFJPJFONN-OUBTZVSYSA-N Phosphorus-32 Chemical compound [32P] OAICVXFJPJFONN-OUBTZVSYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004365 Protease Substances 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000004354 Vulvar Neoplasms Diseases 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000003450 affinity purification method Methods 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003302 anti-idiotype Effects 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000003021 clonogenic effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
208000002925 dental caries Diseases 0.000 description 1
238000013461 design Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000007824 enzymatic assay Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
230000008556 epithelial cell proliferation Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
210000000416 exudates and transudate Anatomy 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
201000000284 histiocytoma Diseases 0.000 description 1
210000004754 hybrid cell Anatomy 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
238000002991 immunohistochemical analysis Methods 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
201000010985 invasive ductal carcinoma Diseases 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000036212 malign transformation Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
230000009681 mesenchymal cell proliferation Effects 0.000 description 1
210000000944 nerve tissue Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
229940043515 other immunoglobulins in atc Drugs 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
229940097886 phosphorus 32 Drugs 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
229940043517 specific immunoglobulins Drugs 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000003335 steric effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000001913 submandibular gland Anatomy 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000012876 topography Methods 0.000 description 1
239000003656 tris buffered saline Substances 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
210000003905 vulva Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Landscapes

Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CA 2116753 1993-03-01 1994-03-01 Anticorps monoclonaux reconnaissant le recepteur du facteur de croissance epidermique (egf), celluces et methodes de production et compositions contenant ces anticorps Expired - Lifetime CA2116753C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CU17/93		1993-03-01
CU1993017		1993-03-01

Publications (2)

Publication Number	Publication Date
CA2116753A1 CA2116753A1 (fr)	1994-09-02
CA2116753C true CA2116753C (fr)	2001-09-04

Family

ID=5459200

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2116753 Expired - Lifetime CA2116753C (fr)	1993-03-01	1994-03-01	Anticorps monoclonaux reconnaissant le recepteur du facteur de croissance epidermique (egf), celluces et methodes de production et compositions contenant ces anticorps

Country Status (2)

Country	Link
CN (1)	CN1103404A (fr)
CA (1)	CA2116753C (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CU24070B1 (es) *	2011-12-27	2015-01-29	Ct De Inmunología Molecular	Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)

1994
- 1994-02-26 CN CN 94104094 patent/CN1103404A/zh active Pending
- 1994-03-01 CA CA 2116753 patent/CA2116753C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CN1103404A (zh)	1995-06-07
CA2116753A1 (fr)	1994-09-02

Legal Events

Date	Code	Title	Description
1996-03-27	EEER	Examination request
2014-05-05	MKEX	Expiry	Effective date: 20140303

Publication	Publication Date	Title
EP0586002B1 (fr)	2000-01-19	Anticorps monoclonaux contre le récepteur du facteur épidermique de croissance, cellules et méthodes pour leur préparation et compositions qui les contiennent
AU2019310803B2 (en)	2022-11-03	Anti-TIGIT antibody and uses thereof
CN113527489B (zh)	2024-04-26	抗cd73的抗体及其用途
KR101671378B1 (ko)	2016-11-01	ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
CN102321173B (zh)	2013-04-03	人源化巨噬细胞抑制因子1单克隆抗体及其应用
RS56219B1 (sr)	2017-11-30	Antitela protiv csf-1r
US20040176576A1 (en)	2004-09-09	Antibodies against cancer
CA2747064A1 (fr)	2010-06-24	Anticorps monoclonaux diriges contre le domaine lg4-5 de la chaine alpha3 de la laminine-5 humaine
CN110563843A (zh)	2019-12-13	一种靶向人vista蛋白的单克隆抗体
AU2021395129A1 (en)	2023-07-06	Cd73 antigen-binding protein and application thereof
CN108883163B (zh)	2022-04-15	用于癌症治疗的抗存活蛋白抗体
IL323270A (en)	2025-11-01	Antibody against PTK7 and its uses
JP2024546939A (ja)	2024-12-26	ヒトｃｄ７３と結合する抗体、その製造方法と使用
EP0156578A2 (fr)	1985-10-02	Procédé de préparation de cellules hybridomes produisant des anticorps monoclonaux spécifiques de tumeurs
CN110642950B (zh)	2021-10-01	一种人源化t细胞活化的v域免疫抑制因子抗原结合片段
CN118063612B (zh)	2024-07-26	抗ror1抗体或其抗原结合片段及其用途
US7550568B2 (en)	2009-06-23	Monoclonal antibodies to human high molecular weight-melanoma associated antigen
CA2116753C (fr)	2001-09-04	Anticorps monoclonaux reconnaissant le recepteur du facteur de croissance epidermique (egf), celluces et methodes de production et compositions contenant ces anticorps
CN110606892B (zh)	2023-09-26	一种高亲和力高生物活性的lag-3抗体及其应用
JP7734856B2 (ja)	2025-09-05	二重特異性抗体及びその使用
WO2020099235A1 (fr)	2020-05-22	Anticorps bispécifiques dirigés contre 90k humain, et soit l'endosialine, soit her3
Patentamt	0	for their production and compositions containing them
CN120040587B (zh)	2025-08-08	抗liv-1抗体或其抗原结合片段及其用途
CN117264065B (zh)	2025-11-18	一种her2抗原结合分子及其应用
TWI904315B (zh)	2025-11-11	人lifr抗原結合蛋白及其製備方法和應用